Abstract

BackgroundAs ovarian cancer stem cells (CSCs) are responsible for tumor initiation, invasion, metastasis, and chemo-resistance, new stratagems that selectively target ovarian CSCs are critically significant. Our previous work have demonstrated that ovarian cancer spheroid cells are tumorigenic and chemo-resistant, and have the properties of ovarian CSCs. Herein, we hypothesized that expressing α-gal epitopes on ovarian spheroid cells may help eliminate CSCs and improve the outcome of therapeutic intervention for ovarian cancer patients.MethodsLentivirus-mediated transfer of a pig α(1,3)galactosyltransferase [α1,3GT] enzyme gene into human ovarian cell line SKOV3 cells formed α-gal epitope-expressing cells (SKOV3-gal cells), and then these cells were maintained in a serum-free culture system to form SKOV3-gal spheroid cells. Efficacy of this cell vaccine was demonstrated in α1,3GT knockout mice (α1,3GT KO mice).ResultsThe antibody titers to α-gal epitopes measured by ELISA were significantly increased in α1,3GT KO mice after immunization with SKOV3-gal spheroid cells. Furthermore, compared with the non-immunized KO mice, the SKOV3 tumors grafted under renal capsules of KO mice immunized with SKOV3-gal spheroid cells grew slower and began to shrink on day 12. Western blot analysis also showed that immunized KO mice can produce effective antibody against certain tumor associated antigens (TAAs) derived from both SKOV3 cells and SKOV3 spheroid cells. The TAAs were further investigated by mass spectrometry and RNA interference (RNAi) technology. The results suggested that antibodies responding to protein c-erbB-2 may be raised in the sera of the mice after immunization with SKOV3-gal spheroid cells. Ultimately, vaccination with SKOV3-gal spheroid cells induced more CD3 + CD4 + T cells in the spleen of immunized mice than non-immunized KO mice.ConclusionsThe results suggest that vaccination using ovarian cancer stem-like cells engineered to express α-gal epitopes may be a novel strategy for treatment of ovarian cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-1973-7) contains supplementary material, which is available to authorized users.

Highlights

  • As ovarian cancer stem cells (CSCs) are responsible for tumor initiation, invasion, metastasis, and chemo-resistance, new stratagems that selectively target ovarian CSCs are critically significant

  • Generation of stable ovarian cancer cell line SKOV3 transfectant expressing α-gal epitopes Porcine α1,3GT cDNA was sub-cloned into pCDHCMV-MCS-EF1-copGFP, α1,3GT recombinant plasmid (Additional file 3: Figure S1)

  • Α-gal epitope expression did not affect the properties of SKOV3-gal cells Previously we reported that ovarian cancer stem-like cells could be enriched by spheroid cell subpopulation under stem cell selection medium [17,18,19]

Read more

Summary

Introduction

As ovarian cancer stem cells (CSCs) are responsible for tumor initiation, invasion, metastasis, and chemo-resistance, new stratagems that selectively target ovarian CSCs are critically significant. It remains critical to develop an effective therapy to reduce the relapse and achieve long-term remissions. Conventional anti-cancer treatments (e.g. chemotherapy and radiation) can often transiently shrink tumors, but these therapies fail to target and kill CSCs, leading to relapse, and death [5]. It is necessary to develop an effective stratagem targeting CSCs. Evidence to date has demonstrated that ovarian CSCs are tumorigenic and chemo-resistant. Elimination of ovarian CSCs, might help improve the sensitivity of chemotherapy drugs and reduce the tumor relapse [6, 7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call